Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
University of Alabama at Birmingham
Mayo Clinic
Pfizer
Turning Point Therapeutics, Inc.
Melanoma and Skin Cancer Trials Limited
M.D. Anderson Cancer Center
NeoImmuneTech
Replimune Inc.
Avenzo Therapeutics, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Auricula Biosciences Inc.
DualityBio Inc.
Inhibrx Biosciences, Inc
Tanabe Pharma America, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
CRISPR Therapeutics
Hookipa Biotech GmbH
Marengo Therapeutics, Inc.
Hoffmann-La Roche
Numab Therapeutics AG
HiberCell, Inc.
Intensity Therapeutics, Inc.
Columbia University
Vaccinex Inc.
Iovance Biotherapeutics, Inc.
Simcha IL-18, Inc.
Atara Biotherapeutics
BeiGene
Cancer Research UK
Elucida Oncology
Federation Francophone de Cancerologie Digestive
Kyowa Kirin Co., Ltd.
Evopoint Biosciences Inc.
Centre Leon Berard
Steba Biotech S.A.
Icahn School of Medicine at Mount Sinai
CARsgen Therapeutics Co., Ltd.
Bristol-Myers Squibb
MedImmune LLC
NBE-Therapeutics AG
Kineta Inc.
Genelux Corporation
Ludwig Institute for Cancer Research
The University of Texas Health Science Center at San Antonio
Vaccinex Inc.
Genocea Biosciences, Inc.
Tarveda Therapeutics
University of California, San Francisco
Rexahn Pharmaceuticals, Inc.